Say Good-bye to the Family Farm
Watson Pharmaceuticals Inc.'s purchase of Schein Pharmaceutical seems to confirm what generics industry experts have known for some time: the industry is consolidating at both the wholesaler and manufacturer levels. The purchase, for $674 million and the assumption of $240 million in debt, is the third time in the past year that a large generics maker has bought a rival. The deal puts Watson, now ranked number four in generics, in a race for first place with Teva Pharmaceutical Industries Inc., which has also been on a buying spree.
You may also be interested in...
New report shows average out-of-pocket cost per prescription of $10.67 in 2019 was unchanged from 2018. But while the number of dispensed drugs barely increased, sales jumped more than 5%.
The merger between virtual care companies Teladoc and Livongo will offer individuals a wide range of tech-enabled care during a time when telehealth continues to grow.
Regeneron's antibody cocktail for SARS-Cov-2 is largely in holding mode for now, but the company announced progress on other fronts including for Dupixent in COPD and the NGF inhibitor fasinumab.